MARKET

ARWR

ARWR

Arrowhead Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

85.64
-0.34
-0.40%
Pre Market: 85.64 0 0.00% 08:47 06/21 EDT
OPEN
85.03
PREV CLOSE
85.98
HIGH
86.71
LOW
84.51
VOLUME
1.73K
TURNOVER
--
52 WEEK HIGH
92.60
52 WEEK LOW
32.86
MARKET CAP
8.91B
P/E (TTM)
-80.2699
1D
5D
1M
3M
1Y
5Y
Arrowhead and Horizon team up in potential $700M collaboration agreement
Arrowhead Pharmaceuticals (ARWR) and Horizon Therapeutics (HZNP) announces a global collaboration and license agreement for ARO-XDH, a potential treatment for people with uncontrolled gout, for as much as $700M.Under the
Seekingalpha · 1h ago
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout; Arrowhead To Receive $40M Upfront
- Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) Arrowhead
Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) Arrowhead · 1h ago
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 2d ago
BRIEF-Arrowhead Pharmaceuticals Says At Annual Meeting Of Stockholders, Michael Perry Did Not Receive Majority Of Votes Cast On His Re-Election To Board
reuters.com · 4d ago
Baird Assumes Arrowhead Pharmaceuticals at Neutral with $85 Price Target
MT Newswires · 06/04 09:56
Dosing underway in Arrowhead Pharma's mid-stage study of ARO-APOC3 in severe hypertriglyceridemia
Arrowhead Pharmaceuticals (ARWR) has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, an investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients
Seekingalpha · 06/03 11:41
BRIEF-Arrowhead Pharmaceuticals Initiates Phase 2B Study Of Investigational Aro-Apoc3 For Treatment Of Severe Hypertriglyceridemia
reuters.com · 06/03 11:35
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company's investigational RNA interference (RNAi) therapeutic being developed as a treatment for...
Business Wire · 06/03 11:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARWR. Analyze the recent business situations of Arrowhead Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARWR stock price target is 91.08 with a high estimate of 106.00 and a low estimate of 44.00.
EPS
Institutional Holdings
Institutions: 424
Institutional Holdings: 79.28M
% Owned: 76.17%
Shares Outstanding: 104.08M
TypeInstitutionsShares
Increased
83
3.71M
New
32
602.46K
Decreased
124
3.46M
Sold Out
49
1.01M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.57%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Chairman/Director
Douglass Given
Chief Executive Officer/President/Director
Christopher Anzalone
Chief Financial Officer
Kenneth Myszkowski
Senior Vice President
James Hamilton
Chief Scientific Officer
Curt Bradshaw
Chief Compliance Officer/General Counsel/Secretary
Patrick O'Brien
Other
James Hassard
Other
Javier San Martin
Lead Director/Independent Director
Michael Perry
Independent Director
Marianne De Backer
Independent Director
Mauro Ferrari
Independent Director
Oye Olukotun
Independent Director
William Waddill
No Data
About ARWR
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.